

Università degli Studi di Brescia

JOINT MEETING 1\* ADVANCED AIRB COURSE IN RADIOBIOLOGY BRESCIA MEETINGS IN RADIATION ONCOLOGY – 2015 EDITION



Nadia Pasinetti 9.10.2015







## **RADIOTHERAPY**

Normal tissue radiation toxicity can influence treatment outcomes, patient quality of life and survivorship.

Despite all progress, the efficacy of radiation-based treatment approaches is still limited by different

- technological, - biological, and
- clinical constraints.



Major issues that can be distinguished are:

1) The intrinsic radiation resistance of several tumors is higher than that of the surrounding normal tissue,

2) The true patho-anatomical borders of tumors or areas at risk are not perfectly identifiable,

3) The treatment volume cannot be adjusted properly during a given treatment series,

4) The individual heterogeneity in terms of tumor and normal tissue responses toward irradiation is immense.

The responses of normal tissue to irradiation can be classified as <u>early</u>, <u>intermediate</u> or <u>late</u> depending on the time it takes for them to develop following radiation exposure.



Barnett GC. et al., Nature Rew Cancer 2009

Università degli Studi di Brescia

Brescia



| Temporal classification        | Tissue                               | Effects   |
|--------------------------------|--------------------------------------|---|
| Early (hours to weeks)         | Hematopoietic<br>Gastrointestinal    | Lymphopenia, neutropenia, thrombopenia, anemia, death (2.5–5 Gy)<br>Bloody diarrhea, denudation of epithelia, destruction of intestinal |
|                                | Cerebrovascular<br>Skin              | Rapid cardiovascular and neurologic breakdown, death (12 Gy+)<br>Erythema, desquamation   |
| Intermediate (weeks to months) | Lung                                 | Acute pneumonitis   |
| Late (months to years)         | Gastrointestinal<br>Lungs<br>Bladder | Epithelial thickening, fibrosis<br>Fibrosis<br>Fibrosis   |
|                                | Heart<br>Kidneys                     | Fibrosis, pericarditis<br>Nephropathy, arterial hypertension, anemia  |
|                                | Liver                                | Hepatitis, rapid loss of function<br>Transient demyelination, leukoencephalopathy, radionecrosis  |



The <u>intermediate effects</u> of radiation damage occur within a few months of radiation exposure. The main form of intermediate radiation response is acute pneumonitis of the lung, which may occur 2-6 months after irradiation.

| Temporal classification        | Tissue                            | Effects  |
|--------------------------------|-----------------------------------|--|
| Early (hours to weeks)         | Hematopoietic<br>Gastrointestinal | Lymphopenia, neutropenia, thrombopenia, anemia, death (2.5–5 Gy<br>Bloody diarrhea, denudation of epithelia, destruction of intestinal<br>crypt cells, death (5–12 Gy) |
|                                | Cerebrovascular<br>Skin           | Rapid cardiovascular and neurologic breakdown, death (12 Gy+)<br>Erythema, desquamation  |
| Intermediate (weeks to months) | Lung                              | Acute pneumonitis  |
| Late (months to years)         | Gastrointestinal                  | Epithelial thickening, fibrosis  |
|                                | Lungs                             | Fibrosis   |
|                                | Bladder                           | FIDrosis<br>Fibrosis poricarditis  |
|                                | Kidneys                           | Nephropathy, arterial hypertension, anemia   |
|                                | Liver                             | Hepatitis, rapid loss of function  |
|                                | CNS                               | Transient demyelination, leukoencephalopathy, radionecrosis  |



| Temporal classification        | Tissue                            | Effects  |
|--------------------------------|-----------------------------------|--|
| Early (hours to weeks)         | Hematopoietic<br>Gastrointestinal | Lymphopenia, neutropenia, thrombopenia, anemia, death (2.5–5 Gy<br>Bloody diarrhea, denudation of epithelia, destruction of intestinal<br>crypt cells, death (5–12 Gy) |
|                                | Cerebrovascular<br>Skin           | Rapid cardiovascular and neurologic breakdown, death (12 Gy+)<br>Erythema, desquamation  |
| Intermediate (weeks to months) | Lung                              | Acute pneumonitis  |
| Late (months to years)         | Gastrointestinal                  | Epithelial thickening, fibrosis  |
|                                | Lungs                             | FIDrosis   |
|                                | Heart                             | Fibrosis pericarditis  |
|                                | Kidneys                           | Nenhronathy, arterial hypertension, anemia   |
|                                | Liver                             | Hepatitis, rapid loss of function  |
|                                | CNS                               | Transient demyelination, leukoencephalopathy, radionecrosis  |



Ionizing radiations are used to cure cancers based on their properties to kill cells by:

- energy deposition in tissues,
- water radiolysis,
- production of free radicals damaging DNA, proteins and lipids.





The <u>target cell concept</u> systein that tissue response to radiation exposure is governed by cell death in a target radiosensitive compartment, often **the survivine** and proliferation of stem or progenitor cells.

> Target cell concept <u>does not</u> <u>reflect</u> what really happen in the vicinity of irradiated organs

Università degli Studi di Brescia

A.O. Spedali Civili di Brescia













Kerns SL et al., Cancer Discovery 2014





Advances in knowledge of <u>tissue and organ biology</u>, <u>mechanisms of injury</u>, <u>development of predictive biomarkers and mechanisms of radioprotection</u> energize the field of normal tissue protection and mitigation.

Since various factors vary among tissues, successful development of radioprotectors/mitigators/treatments may require multiple approaches.

All these efforts to offer considerable improvement in the benefit of anticancer radiotherapy as well as in the management of normal tissues side effects.



